Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.45 |
| ▸ | LMNA | P02545 | 4/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | CRHBP | P24387 | 1/20 | 0.36 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6697673 | 0.90 | MAPT (0.47) | MAPTLMNAATMPOLBCYP1A2 | |
| SCHEMBL6695432 | 0.87 | NPC1 (0.47) | MAPTATMPOLBCYP1A2CYP3A4 | |
| SCHEMBL6701919 | 0.81 | MAPT (0.43) | MAPTLMNAATMPOLBCYP1A2 | |
| SCHEMBL6697467 | 0.81 | MAPT (0.40) | MAPTLMNAATMPOLBCYP1A2 | |
| SCHEMBL6696475 | 0.78 | CRHR1 (0.39) | MAPTLMNAATMCYP1A2CYP3A4 | |
| SCHEMBL6696084 | 0.75 | LMNA (0.49) | MAPTLMNAATMPOLBCYP1A2 | |
| SCHEMBL6694037 | 0.74 | NPC1 (0.49) | MAPTATMPOLBCYP1A2CYP3A4 | |
| SCHEMBL6694814 | 0.72 | CYP1A2 (0.38) | MAPTLMNAATMPOLBCYP1A2 | |
| SCHEMBL7042024 | 0.72 | MAPT (0.46) | MAPTLMNAPOLBCYP1A2CYP3A4 | |
| SCHEMBL6694823 | 0.72 | NPC1 (0.47) | MAPTATMPOLBCYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6835726-B2 | Pyrimidine derivatives | AMGEN INC. | 2004-12-28 | — | — | US | disclosed |
| US-20040006068-A1 | Pyrimidine derivatives | TULARIK INC. | 2004-01-08 | — | — | US | disclosed |
| EP-1056742-B1 | ANTI-VIRAL PYRIMIDINE DERIVATIVES | TULARIK INC (US) | 2003-07-23 | — | — | EP | disclosed |
| US-6528513-B2 | Viricides; especially cytomegalo virus | TULARIK INC | 2003-03-04 | — | — | US | disclosed |
| US-20010018436-A1 | Pyrimidine derivatives | TULARIK INC. | 2001-08-30 | — | — | US | disclosed |
| US-6200977-B1 | USEFUL IN TREATING AND SUPPRESSING HUMAN CYTOMEGALOVIRUS | TULARIK INC. | 2001-03-13 | — | — | US | disclosed |
| EP-1056742-A1 | ANTI-VIRAL PYRIMIDINE DERIVATIVES | TULARIK, INC. (US) | 2000-12-06 | — | — | EP | disclosed |
| WO-1999041253-A1 | ANTI-VIRAL PYRIMIDINE DERIVATIVES | TULARIK INC. (US) | 1999-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010018436-A1 | Pyrimidine derivatives | TYMP, TYMS, UMPS | MAPT 1762/4885LMNA 4485/4885ATM 2349/4885 |
| US-20040006068-A1 | Pyrimidine derivatives | TYMP, TYMS, UMPS | MAPT 1762/4885LMNA 4485/4885ATM 2349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.